Flare Capital Partners

Flare Capital Partners is one of the few US venture firms that is genuinely a healthcare technology specialist rather than a generalist firm with a healthcare practice, and that distinction shapes how founders should engage with the firm. Operating from Boston, Flare focuses exclusively on digital health, health IT and healthcare software, and care delivery and tech-enabled services, with explicit AI focus across the portfolio. The firm does not invest outside healthcare, which means every conversation with Flare is with partners who have spent their careers in the same systems, payers, providers, and regulatory environments that founders are building into. For healthcare AI founders building enterprise software or care delivery platforms, this specialist depth is the central reason to engage.

The investment thesis is anchored in three pillars that together define modern US healthcare technology: digital health, health IT and healthcare software, and care delivery and tech-enabled services. AI is treated as a horizontal capability that increasingly underpins every category, with particular relevance in clinical decision support, payer operations, provider workflow, and care management. Stage focus runs from seed through Series A and Series B, which means Flare engages early enough to shape company-building decisions while reserving the depth of capital and operational support that becomes most valuable at the Series A and B inflection points. The firm’s specialist focus means that diligence is unusually substantive; partners arrive at first meetings already familiar with the relevant payers, the relevant clinical specialty dynamics, and the relevant competitive landscape, which compresses the explanatory burden on founders and shifts the conversation toward strategy and execution.

The specific portfolio detail provided in the source is limited, but Flare has historically been a recognized backer of healthcare technology companies across payer technology, provider workflow, care management, and tech-enabled services. Founders evaluating fit should diligence the current portfolio directly through the firm’s website to understand which categories and stages the firm is most actively deploying into, as healthcare technology investment focus rotates with payer policy, provider economics, and the broader health system technology cycle.

Check sizes typically run between five and twenty-five million dollars, with the firm leading or co-leading at Series A and Series B and taking meaningful seed positions where the founder and category fit are exceptional. The firm prefers to lead or co-lead and to take board roles. Geographic focus is United States, with Boston as the operating base and active deployment across the major US healthcare technology hubs. There is no published hard revenue requirement, but at Series A and Series B, Flare expects credible commercial traction with payers, providers, or other healthcare buyers, customer evidence, and a clear path to category leadership in a defined healthcare segment.

The firm is partner-driven and built around healthcare-specialist operating experience. Decision-making is structured around the firm’s investment committee, with significant weight given to the partner originating the deal. Founders should expect a multi-meeting diligence process, structured engagement with the firm’s deep network of healthcare operators and clinical advisors, and post-investment support that includes board involvement, customer introductions to payers and providers, talent and operating assistance, and downstream introductions to other healthcare-focused investors. The specialist nature of the firm means that post-investment support is unusually concrete and healthcare-specific rather than generic venture support.

Warm introductions through existing Flare portfolio CEOs are the most productive path in, followed by referrals from other healthcare-specialist investors, payer and provider executives, and Boston-based healthcare operators who frequently engage with the firm. Senior healthcare technology executives, clinical leaders, and well-known healthcare academic founders are also strong referral sources. Cold inbound is read but converts more reliably when the company has a specific healthcare-specialist angle that maps directly to the firm’s stated categories. A short, sharp memo that establishes category, payer or provider traction, and a clear healthcare-specific path to scale will materially outperform a generic technology pitch.

Founders should approach Flare when the company is genuinely a US healthcare technology company at the seed, Series A, or Series B stage, when there is credible payer, provider, or other healthcare buyer traction, and when the business is fundamentally a software, applied-AI, or tech-enabled services platform built for healthcare buyers. Flare is not the right fit for non-healthcare technology companies, pure consumer health plays without an enterprise dimension, or therapeutics and devices without a software or services core. For the right US healthcare AI founder, Flare is one of the most valuable specialist partners available, with the depth of operating relationships and category knowledge to materially accelerate company building.